These collective data suggest that interactions between α-SMA, CD44, HA, and osteopontin play a role in the development of crescentic glomerulonephritis and that targeting HA-related actions could yield therapeutic benefits. The gene discussed is CD44; the disease is crescentic glomerulonephritis.